• Type:
  • Category:

BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals, Cutting-Edge Tech & Growth Trajectory with IR

Share

Excerpt

Discover the Q1-2022 financials and insights from BRAIN Biotech AG, a leading European industrial biotechnology company driving the biologization of the industry for a sustainable future.


In this comprehensive video presentation, Michael Schneiders, Investor Relations, provides an in-depth look into BRAIN’s group structure, strategic deals, cutting-edge technology, and financial highlights. Learn about the Breatec deal, PHA 121, the SolasCure partnership, and the groundbreaking BEC patent. Gain insights into the long-term revenue growth trajectory and the company’s response to Covid, supply chain challenges, and inflation.


Understand BRAIN’s guidance and mid-term targets as they continue to innovate and develop bio-based products and solutions for nutrition, health, and the environment.


The BRAIN Group maintains its diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions already successfully employed in the industry. The BRAIN Group has production facilities in Germany, the UK and the US, which, together with the associated biotechnological production expertise, complete the value chain within the Group.


As a United Nations Global Compact participant, BRAIN Biotech AG is committed to aligning strategies and operations with universal human rights, labour, environment and anti-corruption principles and taking actions that advance societal goals.


Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Chapters

  • Introduction
  • Brain at a Glance
  • Brain Group Structure
  • Breatec Deal Summary
  • PHA 121
  • SolasCure
  • BEC Partnership
  • BEC – Patent Published
  • Genome Editing: Platform Business
  • Financial Highlights
  • Long-Term Revenue Growth Trajectory
  • Covid, Supply Chain, Inflation
  • Guidance and Mid-Term Targets

Resources

Presentation
BRAIN Biotech Video Hub
Podcast

Host

Michael Schneiders
IR | BRAIN Biotech AG

Linkedin Envelope

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

February 24, 2022

Duration

15:21

Director

Reviews for BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals, Cutting-Edge Tech & Growth Trajectory with IR

There are currently no reviews for BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals, Cutting-Edge Tech & Growth Trajectory with IR
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

Italy:

Poland:

VERTICALS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

💺 seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top
seat11a - Video Insights for European Financial Markets